The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

Leap Therapeutics' Phase 2 trial data show sirexatamab boosts response rates and survival in MSS colorectal cancer, with ...

Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET. Company Participants. Douglas Onsi - President ...

The following is a summary of “Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration,” published in the March 2025 issue of British Journal ...

The only update for patients with stage IV NSCLC without driver alterations is that patients who have HER2-overexpressing (IHC 3+) disease and good performance status can receive trastuzumab ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today presented updated preliminary data from Part B of the DeFianCe ...

Ended Q4 with $168.1M of cash and cash equivalents and believes current cash will support current and planned operations into 2026. “In ...

Leap Therapeutics (LPTX) presented updated preliminary data from Part B of the DeFianCe study, a Phase 2, open-label, global study of ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024.